Renaissance Technologies
ALXO icon

Renaissance Technologies’s ALX Oncology ALXO Stock Holding History

Renaissance Technologies’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Sell
603,797
-128,802
-18% -$231K ﹤0.01% 2200
2026
Q1 		$1.47M Buy
732,599
+309,500
+73% +$590K ﹤0.01% 2061
2025
Q4 		$478K Buy
423,099
+258,600
+157% +$392K ﹤0.01% 2590
2025
Q3 		$301K Buy
164,499
+79,100
+93% +$68.5K ﹤0.01% 2993
2025
Q2 		$35.4K Buy
85,399
+71,100
+497% +$35.9K ﹤0.01% 3427
2025
Q1 		$8.91K Buy
+14,299
New +$17.2K ﹤0.01% 3394
2024
Q4 		– Sell
-155,300
Closed -$283K – 3547
2024
Q3 		$283K Sell
155,300
-282,900
-65% -$1.05M ﹤0.01% 3002
2024
Q2 		$2.64M Buy
438,200
+204,100
+87% +$2.51M ﹤0.01% 1699
2024
Q1 		$2.61M Sell
234,100
-36,400
-13% -$511K ﹤0.01% 1846
2023
Q4 		$4.03M Buy
270,500
+58,000
+27% +$550K 0.01% 1487
2023
Q3 		$1.02M Buy
212,500
+29,700
+16% +$161K ﹤0.01% 2277
2023
Q2 		$1.37M Buy
182,800
+55,981
+44% +$366K ﹤0.01% 2247
2023
Q1 		$573K Buy
126,819
+31,019
+32% +$235K ﹤0.01% 2809
2022
Q4 		$1.08M Sell
95,800
-74,800
-44% -$840K ﹤0.01% 2486
2022
Q3 		$1.63M Sell
170,600
-57,083
-25% -$665K ﹤0.01% 2160
2022
Q2 		$1.84M Buy
227,683
+78,883
+53% +$859K ﹤0.01% 2244
2022
Q1 		$2.52M Sell
148,800
-19,100
-11% -$326K ﹤0.01% 2059
2021
Q4 		$3.61M Buy
+167,900
New +$7.24M ﹤0.01% 1733

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Renaissance Technologies's ALXO Position: Q2 2026 in Review

Renaissance Technologies reduced its ALX Oncology (ALXO) stake by 18% in Q2 2026, selling an estimated $231K and leaving 603,797 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2200.

Renaissance Technologies first reported a position in ALXO in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.03M in Q4 2023. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Renaissance Technologies held 603,797 shares of ALX Oncology worth $1.25M as of Q2 2026.
  • Renaissance Technologies sold 128,802 ALX Oncology shares in Q2 2026, an estimated $231K.
  • ALX Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2200 holding.
  • Renaissance Technologies first reported a position in ALX Oncology in Q4 2021 and has held it in 18 quarters since.
  • Renaissance Technologies's ALX Oncology position peaked at $4.03M in Q4 2023.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.